Literature DB >> 19674815

Liver X receptor activation restores memory in aged AD mice without reducing amyloid.

Tim Vanmierlo1, Kris Rutten, Jos Dederen, Vincent W Bloks, Leonie C van Vark-van der Zee, Folkert Kuipers, Amanda Kiliaan, Arjan Blokland, Eric J G Sijbrands, Harry Steinbusch, Jos Prickaerts, Dieter Lütjohann, Monique Mulder.   

Abstract

Alterations in cerebral cholesterol metabolism are thought to play a role in the progression of Alzheimer's disease (AD). Liver X receptors (LXRs) are key regulators of cholesterol metabolism. The synthetic LXR activator, T0901317 has been reported to improve memory functions in animal models for AD and to reduce amyloid-β (Aβ) deposition in the brain. Here we provide evidence that long-term administration of T0901317 to aged, 21-month-old APPSLxPS1mut mice restores impaired memory. Cerebral cholesterol turnover was enhanced as indicated by the increased levels of brain cholesterol precursors and the upregulation of LXR-target genes Abca1, Abcg1, and Apoe. Unexpectedly, the improved memory functions in the APPSLxPS1mut mice after T0901317 treatment were not accompanied by a decrease in Aβ plaque load in the cortex or hippocampus DG, CA1 or CA3. T0901317 administration also enhanced cerebral cholesterol turnover in aged C57BL/6NCrl mice, but did not further improve their memory functions. In conclusion, long-term activation of the LXR-pathway restored memory functions in aged APPSLxPS1mut mice with advanced Aβ deposition. However the beneficial effects of T0901317 on memory in the APPSLxPS1mut mice were independent of the Aβ plaque load in the hippocampus, but were associated with enhanced brain cholesterol turnover.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19674815     DOI: 10.1016/j.neurobiolaging.2009.07.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  61 in total

Review 1.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

2.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

Review 3.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

4.  GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses.

Authors:  O Bruno; E Fedele; J Prickaerts; L A Parker; E Canepa; C Brullo; A Cavallero; E Gardella; A Balbi; C Domenicotti; E Bollen; H J M Gijselaers; T Vanmierlo; K Erb; C L Limebeer; F Argellati; U M Marinari; M A Pronzato; R Ricciarelli
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 5.  Nuclear receptors as therapeutic targets for Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  Expert Opin Ther Targets       Date:  2011-07-01       Impact factor: 6.902

Review 6.  Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease.

Authors:  Nicholas F Fitz; Kyong Nyon Nam; Radosveta Koldamova; Iliya Lefterov
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 7.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.

Authors:  Chia-Chen Liu; Chia-Chan Liu; Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Nat Rev Neurol       Date:  2013-01-08       Impact factor: 42.937

Review 8.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

Review 9.  ATP-binding cassette transporter A1: from metabolism to neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Neurobiol Dis       Date:  2014-05-17       Impact factor: 5.996

10.  Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Gary E Landreth; Paige E Cramer; Mitchell M Lakner; John R Cirrito; Daniel W Wesson; Kurt R Brunden; Donald A Wilson
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.